The Drug-Induced Respiratory Disease Website and App

Frequency - Incidence

Incidence of respiratory adverse event(s) due to the specific drug as assessed by number of reported/published cases in the literature. Red digits in stars indicate: 0 = Very rare, questionable signal · 1 = < 10 cases · 2 = 10-50 cases · 3 = 50–100 cases · 4 = 100-200 cases · 5 = >200 cases

Evidence level/grade

Evidence level for respiratory adverse event(s) due to the specific drug as estimated using Hill’s (1965), Naranjo’s (1981), and Bégaud’s (1985) criteria applied to published cases. Blue digits in stars indicate: 0 = Questionable · 1 = Low · 2 = Moderate · 3 = Robust · 4 = Definite · 5 = Unquestionable, pathognomonic

I.a

Pneumonitis (ILD), acute and/or severe (may produce the ARDS pattern)

Publications

Nakano K, Taira S, Ono M, Tomomatsu J, Sasaki T, Shimbashi W, Fukushima H, Yonekawa H, Mitani H, Takahashi S

Incidence and risk factors of interstitial lung disease (ILD) of head and neck cancer patients treated with Cetuximab.

Annals of oncology : official journal of the European Society for Medical Oncology 2017 Oct;28 Suppl 9;ix78

Nakano K, Seto A, Sasaki T, Shimbashi W, Fukushima H, Yonekawa H, Mitani H, Takahashi S

Incidence and risk factors of interstitial lung disease of patients with head and neck cancer treated with cetuximab.

Head & neck. 2019;41(8):2574-2580

Mayfield JD, Mercado CE, Kaye FJ, Mendenhall WM

Cetuximab-associated pulmonary toxicity in concurrent chemoradiation for the treatment of a squamous cell carcinoma of the head and neck.

Head & neck. 2019;41(4):E55-E58

Shablak A, Conn A

A case of fatal cetuximab-induced interstitial lung disease during the first weeks of treatment.

Targeted oncology. 2014;9(2):177-80

Neal JW, Heist RS, Fidias P, Temel JS, Huberman M, Marcoux JP, Muzikansky A, Lynch TJ, Sequist LV

Cetuximab monotherapy in patients with advanced non-small cell lung cancer after prior epidermal growth factor receptor tyrosine kinase inhibitor therapy.

Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer. 2010;5(11):1855-8

Lai JI, Wang WS, Lai YC, Lin PC, Chang SC

Acute interstitial pneumonitis in a patient receiving a FOLFOX-4 regimen plus cetuximab treated with pulse therapy.

International journal of clinical pharmacology and therapeutics. 2010;48(7):425-8